Newron Pharmaceuticals Nominates Dr. Chris Martin as Independent Chairman

Newron Pharmaceuticals has proposed Dr. Chris Martin, an accomplished biopharma entrepreneur, as the new Independent Chairman. Martin, former CEO of ADC Therapeutics, is set to replace Dr. Ulrich Köstlin, who will retire following the company's Annual General Meeting (AGM) on April 23, 2025. Martin is recognized for his leadership in biopharma, having raised over $1.4 billion to support his ventures.

Dr. Martin's tenure at ADC Therapeutics saw the company grow from a start-up to a NYSE-listed leader. His achievements include co-founding Spirogen Ltd, later sold to AstraZeneca. His election as Chairman is expected to bring valuable expertise to Newron as it advances its novel schizophrenia treatment, evenamide, currently in Phase III trials.

CEO Stefan Weber and the board expressed confidence in Martin's capability to guide Newron's strategic initiatives. Martin's appointment marks him as the third Independent Non-Executive Director in 24 months, signaling a strategic shift for Newron's board.